Tisotumab vedotin in patients with advanced or metastatic solid tumours (InnovaTV 201): a first-in-human, multicentre, phase 1–2 trial

Tisotumab vedotin is a first-in-human antibody–drug conjugate directed against tissue factor, which is expressed across multiple solid tumour types and is associated with poor clinical outcomes. We aimed to establish the safety, tolerability, pharmacokinetic profile, and antitumour activity of tisot...

Full description

Saved in:

Bibliographic Details
Published in:	The lancet oncology Vol. 20; no. 3; pp. 383 - 393
Main Authors:	de Bono, Johann S, Concin, Nicole, Hong, David S, Thistlethwaite, Fiona C, Machiels, Jean-Pascal, Arkenau, Hendrik-Tobias, Plummer, Ruth, Jones, Robert Hugh, Nielsen, Dorte, Windfeld, Kristian, Ghatta, Srinivas, Slomovitz, Brian M, Spicer, James F, Yachnin, Jeffrey, Ang, Joo Ern, Mau-Sørensen, Paul Morten, Forster, Martin David, Collins, Dearbhaile, Dean, Emma, Rangwala, Reshma A, Lassen, Ulrik
Format:	Journal Article
Language:	English
Published:	England Elsevier Ltd 01.03.2019 Elsevier Limited
Subjects:	Alopecia Angiogenesis Appetite loss Biology Bladder cancer Cell cycle Cervical cancer Conjunctivitis Constipation Cytotoxicity Diabetes mellitus Diabetes mellitus (non-insulin dependent) Diarrhea Drug dosages Endometrial cancer Endometrium Esophagus Fatigue Fever Head & neck cancer Hematology, Oncology, and Palliative Medicine Hypoxia Infections Inflammatory bowel disease Lung cancer Medical prognosis Metastases Metastasis Monoclonal antibodies Mucositis Nausea Neutropenia Oncology Ovarian cancer Pain Patients Peripheral neuropathy Prostate Prostate cancer Sepsis Solid tumors Squamous cell carcinoma Studies Targeted cancer therapy Tumors Vomiting
ISSN:	1470-2045, 1474-5488, 1474-5488
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!